Market Research Logo

Australia Pharmaceuticals and Healthcare Report Q4 2017

BMI View: Against a backdrop of a growing and ageing population and an increasing demand formedicines, the Australian government will remain highly focused on cost containment within thepharmaceuticals and healthcare sector. This will continue to create revenue challenges for multinationalpharmaceutical firms. While innovative pharmaceutical treatments will stand to gain from the introductionof a Priority Review and a Provisional Approval process in the country, the net benefit will remainconstrained by the country's difficult listing process.

Headline Expenditure Projections

Pharmaceuticals: AUD13.5bn (USD10.03bn) in 2016 to AUD13.71bn (USD10.63bn) in 2017; 1.6% inlocal currency terms and 5.9% in US dollar terms.

Healthcare: AUD169.08bn (USD125.68bn) in 2016 to AUD176.27bn (USD136.61bn) in 2017; 4.25%in local currency terms and 8.7% in US dollar terms.

Risk/Reward Index

Against a backdrop of high per capita drug spending and a growing and ageing population, newopportunities will continue to drive the innovative drug market in Australia. This is reflected in thecountry's score of 77.5 out of 100.0 in BMI's Innovative Pharmaceuticals Risk/Reward Index. Thegovernment's commitment to enforce drug price controls and promote the consumption of lower-valuegeneric medicines in place of patented medicines, as a means to reduce pharmaceutical expenditure, willpose a significant commercial threat to multinational pharmaceutical firms.


BMI Industry View
Table: Headline Pharmaceuticals And Healthcare Forecasts (2015-2021)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2013-2021)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2013-2021)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2013-2021)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2013-2021)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2013-2021)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2013-2021)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2013-2021)
Australia
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2013-2021)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Australia 2015-2021)
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2015-2021)
Industry Risk/Reward Index
Asia Pacific Pharmaceuticals: Diverse Opportunities And Inherent Risks
Australia - Q4 2017
Regulatory Review
Intellectual Property Issues
Pricing And Reimbursement Regime
Market Overview
Healthcare Sector
Research & Development
Clinical Trials
Epidemiology
Table: Estimated Number Of New Cases Of Cancer In Australia
Competitive Landscape
Research-Based Industry
Table: Multinational Market Activity
Pharmaceutical Distribution
Company Profile
Australian Pharmaceutical Industries
CSL
GlaxoSmithKline
Mayne Pharma Group
Sanofi
Sigma
Demographic Forecast
Demographic Outlook
Table: Population Headline Indicators (Australia 1990-2025)
Table: Key Population Ratios (Australia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Australia 1990-2025)
Table: Population By Age Group (Australia 1990-2025)
Table: Population By Age Group % (Australia 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Table: Indicators - Rationale And Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report